Heavy Metal Index
Ask the IndexAboutIndex Pro

Staff Report — CPSIA Section 101(b): Functional Purpose Exception from Lead Content Limit for Children's Products for a Specific Product, Class of Product, Material, or Component Part

Cite this pageVersion history

Overview

A 26-page U.S. Consumer Product Safety Commission staff report dated November 2012, bearing the standard CPSC staff caveat that “these comments are those of the CPSC staff and have not been reviewed or approved by, and may not necessarily reflect the views of, the Commission.” The report addresses the third of three statutory criteria the Commission must find to grant a functional-purpose exception from the CPSIA Section 101(a) 100 ppm total-lead content limit for children’s products: that the exception “will have no measurable adverse effect on public health or safety,” where the Public Law 112-28 amendment to §101(b) defines “no measurable adverse effect” as “no measurable increase in blood lead levels of a child.” Staff derive a quantitative interpretation: a measurable BLL increase is approximately 0.8 µg/dL, and the daily exposure to lead from a children’s product that would produce that BLL increase is approximately 2.2 µg/day. The report contains no primary lead-occurrence measurements; it is a methodology and threshold-derivation document built from published BLL biokinetic modelling (EPA IEUBK), the Lanphear et al. (2005) international pooled BLL–IQ dose-response analysis, the Parsons et al. (2001) interlaboratory BLL-reference-material analysis, and the OEHHA (2007) child-specific benchmark BLL-change framework, and includes a January–March 2012 external scientific peer review by five reviewers with staff responses.

Key numbers

  • Statutory phased substrate-lead reduction (p. 1): the Consumer Product Safety Improvement Act of 2008 (CPSIA) §101(a) set 600 ppm lead in children’s products effective February 10, 2009, then 300 ppm effective August 14, 2009, then 100 ppm effective August 14, 2011 unless the Commission determines that limit is not technologically feasible. The Commission did not so determine, so the 100 ppm limit binds children’s products manufactured after August 14, 2011 except where the §101(b) exception applies.
  • Three §101(b) statutory exception criteria, as amended by Public Law 112-28 (p. 1; Appendix A p. A-1, quoting 15 USC §1278a(b)(1)(A)): the Commission may grant an exception only if it finds (i) the product, class of product, material, or component part requires the inclusion of lead because it is not practicable or technologically feasible to manufacture it by removing the lead or making the lead inaccessible; (ii) the product or part is not likely to be placed in the mouth or ingested, taking into account normal and reasonably foreseeable use and abuse by a child; and (iii) the exception will have no measurable adverse effect on public health or safety. Subparagraph (B) defines “no measurable adverse effect” as “no measurable increase in blood lead levels of a child.”
  • Reference national BLL distribution in children ages 1–5 (p. 3, CDC NHANES 2007–2008 via CDC 2012): median (50th percentile) 1.4 µg/dL; 95th percentile 4.1 µg/dL. Geometric-mean BLL for U.S. children ages 1–5 is reported as approximately 1.5 µg/dL in footnote 4 (citing CDC 2012). Historical trend, cited to CDC 2009: during 1988–1994, 4.4 % of children ages 1–5 had BLL ≥10 µg/dL; during 1999–2004, that fraction had fallen to 1.4 % (p. 3, CDC 2009 citation).
  • Lanphear et al. (2005) pooled BLL–IQ dose-response model (p. 3 with citation to Environ Health Perspect 113:894–899): the international pooled analysis of children with BLLs in the 2.4–30 µg/dL range fits a log-linear model with adjustment for covariates of the form Change in IQ = ln(BLL) × (−2.7). The 95 % confidence interval on the coefficient is (−3.74, −1.66). The model is non-linear: incremental IQ loss per 1 µg/dL BLL increase is larger at lower BLLs (BLLs <7.5 µg/dL or <10 µg/dL produce a steeper slope than BLLs already in the higher range).
  • IQ loss over BLL 1 → 10 µg/dL (p. 4): point estimate 6.2 IQ points total over the 1–10 µg/dL BLL range, equivalent to an average of 0.69 IQ points per 1 µg/dL BLL increase. Using the upper bound of the 95 % CI on the coefficient (−3.74), the same 1 → 10 µg/dL change predicts a loss of 8.6 IQ points (average 0.96 IQ points per 1 µg/dL BLL increase). Using the lower bound (−1.66): 3.8 IQ points total (average 0.42 per 1 µg/dL). For children’s-products evaluation, staff selected the upper bound of the 95 % CI (−3.74; 0.96 IQ points per 1 µg/dL) as the more health-protective option (p. 4).
  • Parsons et al. (2001) interlaboratory BLL reference-material certifications (p. 7, citing Spectrochim Acta Part B 56:1593–1604): four blood-lead reference materials, analysed by eight referee laboratories in the New York State proficiency-testing programme using three different analytical methods across nine datasets, were certified at all-method means ± between-laboratory SDs of 5.9 ± 0.4 µg/dL, 14.5 ± 0.6 µg/dL, 42.2 ± 1.8 µg/dL, and 76.0 ± 2.2 µg/dL. Staff applied the ±0.4 µg/dL between-laboratory standard deviation from the lowest-concentration reference (5.9 µg/dL sample) as the practical estimate of measurement precision at BLLs comparable to those in current U.S. children.
  • Definition of “measurable increase in BLL” (p. 8, p. 12): approximately two times the standard deviation of the lowest-BLL reference material ≈ 0.8 µg/dL. Staff explicitly compare this 0.8 µg/dL threshold to the OEHHA (2007) child-specific benchmark BLL change of 1 µg/dL and to the OEHHA-stated correspondence “1 µg/dL increase in BLL ≈ 1 IQ point loss.” Staff note that the de minimus language in OEHHA (2007) (“changes in blood lead less than the adopted [1 µg/dL change] are expected to cause no measurable adverse effect”) is the same statutory phrasing used in CPSIA §101(b)(1)(A)(iii) and that “this may not be coincidental.”
  • CDC 42 CFR §493.937 clinical-laboratory performance criteria for BLL proficiency testing (p. 6): acceptable error for BLL is ±4 µg/dL or ±10 %, whichever is greater for samples within the clinically relevant range of values (1 µg/dL to >80 µg/dL; up to 40 µg/dL the allowance is ±4 µg/dL, above 40 µg/dL the allowance is ±10 % of target). The CDC Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP, November 16–18, 2010 meeting) voted unanimously to recommend tightening the criterion to ±2 µg/dL or ±10 %, whichever is greater.
  • IEUBK biokinetic-model derivation of the 2.2 µg/day exposure threshold (p. 9): using the EPA Integrated Exposure Uptake BioKinetic Model for Lead in Children (Windows version IEUBKwin v1.1 build 11, February 2010, 32-bit), staff ran the model with all default inputs (default geometric standard deviation GSD = 1.6; default absorption 50 % for diet and water, 30 % for soil and dust) for the 0–84-month age range. The default-input geometric mean BLL is 2.730 µg/dL with a calculated 95th percentile of 5.915 µg/dL. Adding a hypothetical additional daily lead exposure of 2.2 µg/day (using a 50 % absorption assumption for the lead-containing children’s product, chosen as the more health-protective default rather than the 30 % soil-and-dust default) produces a geometric mean of 3.088 µg/dL with a 95th percentile of 6.690 µg/dL — i.e., a 95th-percentile BLL shift of approximately 0.8 µg/dL, the operational definition of a measurable BLL increase. Hence staff identify 2.2 µg/day as the daily-exposure threshold below which exception products will not result in a measurable BLL increase.
  • IQ-loss equivalent of an 0.8 µg/dL BLL increase (p. 9–10): approximately 0.6 IQ points using the 0.69 IQ-points-per-1 µg/dL central estimate, or approximately 0.8 IQ points using the 0.96 IQ-points-per-1 µg/dL upper-bound estimate. Staff frame both as below the OEHHA (2007) de minimus criterion (1 IQ point) and the EPA (2008) NAAQS-framework value (2 IQ points; 73 FR 67000, 67005), and conclude (p. 11) that this level of population-average IQ change “would not be observable in an individual.”
  • Lead-particle-inhalation route considered and bounded (p. 13): staff conclude that exposure to lead through inhalation of particles released into the air during normal use of children’s products is uncommon because (i) lead and lead compounds used in consumer products are not volatile and (ii) significant releases of lead-containing particles from products into the air are not expected for most products. Inhalation must nonetheless be assessed case-by-case in any exception petition.
  • §101(b) staff recommendation (p. 13): the statutory condition that an exception “will have no measurable adverse effect on public health or safety” is met if a child’s potential exposure to lead from the excepted product is estimated to result in an increase in BLL of less than 0.8 µg/dL, corresponding to a daily exposure of approximately 2.2 µg/day. Staff specify that exception evaluations should rest on estimated normal and reasonably foreseeable use and abuse, including (a) wipe-sampling to estimate transfer of lead from the product surface to the child’s hands and then to the mouth, and (b) case-by-case assessment of any inhalation of lead-containing particles. Staff explicitly acknowledge these conclusions are subject to change as new information becomes available.
  • Bicycle / motor sports / tractor-toy precedent (p. 13): staff note that for previously submitted exclusion petitions (bicycles, motor sports equipment, brass parts on a tractor toy), the actual estimated lead exposure from the potentially excepted products was considerably less than the 2.2 µg/day threshold; nonetheless, exposure must be assessed product-by-product.
  • External peer review (Appendix B, p. B-1 to B-9): in January 2012 CPSC staff sought external scientific peer review of the draft report; comments from five reviewers were received in March 2012; staff revised the report based on the comments. The appendix tabulates 26 named comments with staff responses, including reviewer concerns about (i) population-versus-individual framing of IQ effects, (ii) the non-linear concentration–response curve at low BLLs, (iii) sensitivity-subgroup protection, (iv) the OEHHA de minimus statutory language, and (v) the appropriateness of the IEUBK model inputs (mean intake, GSD, averaging time).

Methods (brief)

This is a regulatory-derivation document, not an analytical-chemistry study. The report has no field sampling, no laboratory analysis of primary samples, and no primary measurement of lead. Its methodology consists of: (i) selecting a quantitative definition of “measurable increase in BLL” from published interlaboratory-validation data on certified reference materials (Parsons et al. 2001 mean ± between-laboratory SD at the lowest reference concentration); (ii) applying the published Lanphear et al. (2005) log-linear BLL–IQ dose-response model to convert the BLL increase into an IQ-loss estimate, using the upper bound of the 95 % confidence interval on the coefficient as the health-protective option; (iii) running the EPA IEUBK biokinetic model for children aged 0–84 months at default inputs (GSD = 1.6, 50 % absorption for product-derived lead, 30 % for soil/dust) to identify the daily incremental exposure that shifts the modelled 95th-percentile BLL by the measurable-increase threshold; and (iv) cross-comparing the resulting IQ-loss estimate against the OEHHA (2007) child-specific benchmark BLL change (1 µg/dL ≈ 1 IQ point) and the EPA (2008) NAAQS framework for lead (which treated up to a 2-point IQ loss as the basis for the air-quality standard). External peer review of the draft was conducted in January–March 2012 by five reviewers (charges and itemised comment-response tables appear in Appendix B). The methodology is documentary and biokinetic-modelling-based; reproducibility depends on the cited published inputs (CDC NHANES, Lanphear 2005, Parsons 2001, OEHHA 2007, EPA IEUBK source code) rather than on novel measurement procedure.

Implications

  • Certification (HMTc): This source establishes the U.S. federal regulatory ceiling and the staff-derived public-health-protection methodology for any children’s-product category for which a §101(b) functional-purpose exception from the CPSIA 100 ppm substrate-lead content limit might be petitioned. The binding floor for HMTc certification of US-marketed children’s products is the 100 ppm substrate limit codified by CPSIA §101(a); any HMTc threshold meeting that 100 ppm value is appropriately tagged regulatory-alignment under Part 19 rationale conventions and any HMTc threshold set below 100 ppm should be tagged precautionary with the rationale documented. The staff-derived 2.2 µg/day daily-exposure ceiling (and the 0.8 µg/dL BLL-increase ceiling) are CPSC’s operational definitions of “no measurable adverse effect on public health or safety” for the §101(b) exception decision, not direct content-limit floors — they are exposure-based, not concentration-based, and are decisive at the point where an exception petition is being evaluated, not at the point of routine certification. The staff acknowledgement (p. 9, p. 12) that the de minimus phrasing in OEHHA (2007) and the “no measurable adverse effect” phrasing in CPSIA §101(b)(1)(A)(iii) are likely not coincidental is relevant background for any HMTc rationale that aligns its lead thresholds to a child-specific de minimus framework rather than to a feasibility-driven or precautionary one.
  • Courses: Useful as a worked example of how a federal agency derives a quantitative health-protection criterion from published biokinetic models, interlaboratory measurement-precision studies, and dose-response meta-analyses — i.e., how “no measurable adverse effect” gets operationalised when the statute requires a measurable-effect threshold but provides no number. The peer-review appendix is a transparent record of the reviewer–staff disagreements (population-vs-individual framing, non-linearity of the low-BLL dose-response, sensitivity-subgroup protection) and is instructive for QA and regulatory-affairs students learning how peer-review feedback gets integrated into a final staff position.
  • App: Not directly relevant to the consumer-app contamination_profile ingestion path. The CPSIA §101(b) statutory scope applies to product substrate and component-part total-lead content, not to food contamination, and the 2.2 µg/day exposure threshold is a regulatory decision criterion for product petitions rather than a per-day intake guideline for individual consumers. The CDC NHANES reference BLL statistics (median 1.4 µg/dL, 95th percentile 4.1 µg/dL for U.S. children ages 1–5) are appropriate context for any future app surface that shows population-level BLL benchmarks alongside food-derived lead-exposure estimates.

Update history

No substantive edit history is available in this build. The full commit record is available in git.

Referenced by